+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Regenerative Medicine Market: By Therapy; By Product; By Application; By Geography - Forecast 2016-2022

  • ID: 3974181
  • Report
  • September 2017
  • 136 pages
  • IndustryARC
1 of 3
Regenerative medicines are capable of restoring the functionality of cells & tissues by treating a patient with laboratory grown cells and tissues. Regenerative medicines are used in a wide range of degenerative disorders such as dermatology, neurodegenerative diseases, cardiovascular and orthopaedic applications. Globally, development of efficient and advance technology in tissue and organ regeneration, growing funding from government and private organizations to support the development of regenerative medicines products, rise in the awareness among people regarding regenerative medicine, increasing government initiative across the globe, and growing aging population and healthcare expenditure are the prime growth drivers of global regenerative medicine market. In addition, Emergence of utilization of nanomaterial in wound care, drug delivery, and immunomodulation, increase in adoption of regenerative medicine for peripheral artery diseases, and emerging economies such as China, India and others, will create new opportunities for global regenerative medicine market. However, higher cost of the research and development, and complex government approval processes are the key restraints for global regenerative medicine market.

Geographically North America dominated global regenerative medicine market because of high medical reimbursement facilities, and technological advancement. Asia Pacific is projected to have fastest growth, owing to rapidly increasing aging population and per capita healthcare expenditure, rise in consumer awareness, higher focus on research in regenerative medicines especially in Japan, favourable government policies, modernization of healthcare infrastructure, and growing medical tourism industry in developing nations such as China, and India in this region. Among all the application, orthopaedic & musculoskeletal spine segment has the highest market share in global regenerative medicine market due to higher prevalence of musculoskeletal cases and growing investments in orthopaedic research.

This report identifies the global regenerative medicine market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global regenerative medicine market.

This report segments global regenerative medicine market on the basis of therapy, product, application, and regional market as follows:
Regenerative Medicine Market, By Therapy: Cell Therapy, Gene Therapy, Tissue Engineering, and Immunotherapy
Regenerative Medicine Market, By Product: Autologous Cell-Based Products, Allogeneic Cell-Based Products, and Acellular Products
The report has focused study on regenerative medicine market by basis of application such as: Orthopedic & Musculoskeletal Spine, Dermatology, Cardiovascular, Central Nervous System, Oncology, Diabetes, and Others
This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region
This report identifies all the major companies operating in the regenerative medicine market. Some of the major companies’ profiles in detail are as follows:
Japan Tissue Engineering Co., Ltd
Vertex Pharmaceuticals Incorporated
Cytori Therapeutics Inc.

Celgene Corporation
Acelity (KCI Licensing)
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
Note: Product cover images may vary from those shown
2 of 3
1. Regenerative Medicine Market – Market Overview

2. Executive Summary

3. Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End User Profiling
3.5. Top 5 Financials Analysis

4. Regenerative Medicine Market– Market Forces
4.1. Drivers
4.1.1. Development of efficient and advance technology in tissue and organ regeneration
4.1.2. Growing funding from government and private organizations to support the development of regenerative medicines products
4.2. Restraints
4.2.1. Higher cost of research and development
4.3. Opportunities
4.3.1. Emerging economies
4.4. Challenges
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition

5. Regenerative Medicine Market– Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors

6. Regenerative Medicine Market, By Therapy
6.1. Cell Therapy
6.2. Gene Therapy
6.3. Tissue Engineering
6.4. Immunotherapy

7. Regenerative Medicine Market, By Product
7.1. Autologous Cell-Based Products
7.2. Allogeneic Cell-Based Products
7.3. Acellular Products

8. Regenerative Medicine Market, By Application
8.1. Orthopedic & Musculoskeletal Spine
8.2. Dermatology
8.3. Cardiovascular
8.4. Central Nervous System
8.5. Oncology
8.6. Diabetes
8.7. Others

9. Regenerative Medicine Market, By Geography
9.1. Europe
9.1.1. Germany
9.1.2. France
9.1.3. Italy
9.1.4. Spain
9.1.5. Russia
9.1.6. U.K.
9.1.7. Rest of Europe
9.2. Asia Pacific
9.2.1. China
9.2.2. India
9.2.3. Japan
9.2.4. South Korea
9.2.5. Rest of Asia-Pacific
9.3. North America
9.3.1. U.S.
9.3.2. Canada
9.3.3. Mexico
9.4. Rest of the World (RoW)
9.4.1. Brazil
9.4.2. Rest of RoW

10. Regenerative Medicine – Market Entropy
10.1. Expansion
10.2. Technological Developments
10.3. Merger & Acquisitions, and Joint Ventures
10.4. Supply- Contract

11. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
11.1. Japan Tissue Engineering Co., Ltd
11.2. Vertex Pharmaceuticals Incorporated
11.3. Cytori Therapeutics Inc.
11.4. Celgene Corporation
11.5. Acelity (KCI Licensing)
11.6. Nuvasive, Inc.
11.7. Organogenesis Inc.
11.8. Vericel Corporation
11.9. Cytori Therapeutics Inc.
11.10. Stemcells, Inc.
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"

12. Appendix
12.1. Abbreviations
12.2. Sources
12.3. Research Methodology
12.4. Bibliography
12.5. Compilation of Expert Insights
12.6. Disclaimer
Note: Product cover images may vary from those shown
3 of 3


4 of 3